Form 4: Arcellx Insider Reports Merger-Related Transactions

Rami Elghandour, Director and Officer of Arcellx, Inc., filed a Form 4 detailing transactions related to the company's merger with Gilead Sciences, Inc.

Summary

• This filing is a Form 4, reporting changes in beneficial ownership for Rami Elghandour, who holds positions as Director and Officer at Arcellx, Inc.
• The transactions reported occurred on April 28, 2026, and are related to the merger of Arcellx, Inc. with Gilead Sciences, Inc.
• Elghandour's common stock holdings were exchanged as part of the merger, with shares tendered for a cash payment and a contingent value right (CVR).
• Options and restricted stock units (RSUs) held by Elghandour were also canceled and converted into rights to receive cash payments and CVRs.
• Specific details include the exchange of stock options for cash payments based on the difference between the closing amount and the exercise price, plus CVRs.
• Restricted stock units were converted into cash payments equal to the closing amount per share, plus CVRs, with performance-based RSUs adjusted for actual performance.
• The filing also notes beneficial ownership of shares held by trusts and a family charitable foundation, with disclaimers of pecuniary interest where applicable.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive filing, as it confirms the execution of a significant merger with a substantial cash payout and contingent value rights for shareholders and insiders, reflecting a successful transaction.

Positives

• The merger with Gilead Sciences, Inc. provides a significant cash payout of $115.00 per share, plus a contingent value right (CVR) of $5.00 per CVR.
• All outstanding stock options were converted into cash payments, representing the 'in-the-money' value of the options.
• Restricted stock units, including performance-based ones, were converted into cash and CVRs, providing value to holders.
• The reporting person, Rami Elghandour, is a key insider (Director and Officer) participating in the merger's financial benefits.

Negatives

• The filing details the cancellation of existing stock options and RSUs as part of the merger, which are no longer held by the reporting person.
• The contingent value right (CVR) represents a future payment that is contingent on specific events and may not be fully realized.

Risks

• The value of the Contingent Value Right (CVR) is contingent and subject to the terms and conditions of a separate agreement, meaning the $5.00 payment is not guaranteed.
• Withholding taxes apply to cash payments received from the cancellation of options and RSUs, reducing the net amount received.
• The reporting person disclaims beneficial ownership of shares held in a spousal lifetime access trust except to the extent of his pecuniary interest, indicating potential complexity in beneficial ownership.

Future Outlook

The future outlook is tied to the performance-based vesting conditions of certain RSUs and the realization of the Contingent Value Rights (CVRs), which are subject to specific terms and conditions outlined in separate agreements.

Management Comments

• The reporting person disclaims beneficial ownership of shares held by a spousal lifetime access non-grantor trust except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for Section 16 or any other purpose.
• The reporting person disclaims beneficial ownership of shares held by a spousal lifetime access non-grantor trust of which the Reporting Person is a beneficiary except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for Section 16 or any other purpose.
• The reporting person has voting and investment power over all securities owned by the family charitable foundation.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects a significant event for Arcellx, Inc., namely its acquisition by Gilead Sciences, Inc. Such filings are standard during M&A processes, detailing how insider equity holdings are converted into cash and potential future payments, which is a common outcome in the biotechnology and pharmaceutical sectors when larger companies acquire smaller, innovative firms.

Comparison to Industry Standards

• The transaction structure, involving a cash payment plus a Contingent Value Right (CVR), is a common mechanism in M&A deals within the biotechnology and pharmaceutical industries. Companies like Pfizer, Bristol Myers Squibb, and Merck have frequently utilized CVRs in their acquisitions to bridge valuation gaps and incentivize continued performance post-acquisition.
• The cash component of $115.00 per share represents a substantial premium, typical for acquisitions of companies with promising drug pipelines, aiming to reflect the future potential value that may be difficult to quantify precisely at the time of the deal.
• The conversion of stock options and RSUs into cash and CVRs is a standard practice, ensuring that all forms of equity compensation are addressed in the acquisition, aligning with industry norms for executive and employee compensation packages.

Stakeholder Impact

• Shareholders: Will receive $115.00 per share in cash plus one CVR per share, representing a significant return on investment.
• Option and RSU Holders (including management): Will receive cash payments and CVRs, converting their equity awards into immediate and potential future value.
• Employees: Those holding RSUs or options will benefit from the merger's financial terms.
• Creditors: The acquisition by Gilead Sciences, a larger entity, may provide increased financial stability for Arcellx's ongoing operations or obligations.

Next Steps

• Shareholders and option/RSU holders will receive the cash payments and CVRs as per the merger agreement.
• The realization of CVR payments will depend on the achievement of specific milestones outlined in the contingent value rights agreement.
• Arcellx, Inc. will become a wholly owned subsidiary of Gilead Sciences, Inc.

Key Dates

Recommendation

This filing is a Form 4 reporting insider transactions related to a completed merger. It confirms the financial terms of the acquisition for an insider and does not provide new strategic information or guidance that would warrant a buy or sell recommendation. For existing Arcellx shareholders, the transaction has concluded, and their focus would now be on the value of the CVRs. For potential investors, the opportunity to invest in Arcellx as an independent entity has passed, and any investment decision would now relate to Gilead Sciences.

Keywords

Arcellx, ACLX, Form 4, Insider Trading, Merger, Gilead Sciences, Stock Options, Restricted Stock Units, Contingent Value Right, Beneficial Ownership, Rami Elghandour